321 related articles for article (PubMed ID: 36272052)
1. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
Beavers CJ
Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052
[TBL] [Abstract][Full Text] [Related]
2. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
[TBL] [Abstract][Full Text] [Related]
3. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
5. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
Kintscher U
Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
[TBL] [Abstract][Full Text] [Related]
8. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
9. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
Haller H
Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
[TBL] [Abstract][Full Text] [Related]
10. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F
Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983
[TBL] [Abstract][Full Text] [Related]
11. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
DeFronzo RA; Bakris GL
Diabetes Obes Metab; 2022 Jul; 24(7):1197-1205. PubMed ID: 35302284
[TBL] [Abstract][Full Text] [Related]
12. Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease.
Shah M; Awad AS; Abdel-Rahman EM
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834929
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
[TBL] [Abstract][Full Text] [Related]
14. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
Salukhov VV; Shamkhalova MS; Duganova AV
Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
[TBL] [Abstract][Full Text] [Related]
16. Cardiorenal benefits of finerenone: protecting kidney and heart.
González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Agarwal R; Filippatos G; Pitt B; Anker SD; Rossing P; Joseph A; Kolkhof P; Nowack C; Gebel M; Ruilope LM; Bakris GL;
Eur Heart J; 2022 Feb; 43(6):474-484. PubMed ID: 35023547
[TBL] [Abstract][Full Text] [Related]
18. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
20. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
Georgianos PI; Agarwal R
Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]